1Sanchorawala V. Light-chain (AL) amyloidosis:diagno sis and treatment[J].Clin J Am Soc Nephrol, 2006, 1 (6):1331- 1341.
2Gertz M A, Comenzo R, Falk R H, et al. Definition of organ involvement and treatment response in irnmuno globulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004[J].Am J Hematol,2005,79(4) :319-328.
3Merlini G, Bellotti V. Molecular mechanisms of amyloi dosis[J].N Engl J Med,2003,349(6) :583 596.
4Comenzo R L, Gertz M A. Autologous stem cell trans- plantation for primary systemic amyloidosis[J]. Blood, 2002,99(12) ..4276-4282.
5Desai HV, Aronow WS, Peterson SJ, e! al. Cardiac amyIoidosis: approaches to diagnosis and management. [J]Cardiol Bey, 2010,18(1):1-11.
6Goldman L, Ausiello D. Cecil textbook of medicine. [J]Philadelphia: Saunders. 2004 : 171.
7Kyle RA,Gertz MA. Primary systemic amyloidosis:clinical and laboratory in 474 cases. [J]Semin Hematol, 1995, 32:45-59.
8Kholov6 l, Niessen HW. Amyloid in the cardiovascular system:a review. [J] Clin Pat hol, 2005, 58 (2) : 125--133.
9Qu z, Zheng X, Wang SX, et al. Clinical and pathdosical featuresofrenal amyloidceis : an analysis of 32 patients in a single Chinesecentre. [J]Nephrology (Carhon), 2010, 15 (1) :102-107.
10Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus meJlphalan plus dexamethasone for Alamyloidosis. [J]N Engl, 2007, 357: 1083--1093.
